Analysts expect Damora Therapeutics, Inc. to report revenue of 0.00 for Q4 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 |
|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | - | - |
| High Estimate | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Low Estimate | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consensus Estimate | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Damora Therapeutics, Inc. to report earnings per share of -2.90 for Q4 24, against a range of -3.00 to -2.80. The most recent reported quarter, Q1 26, came in at -0.62, a 67.6% miss against the -0.37 consensus.
| Metric | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -4.92 | -3.39 | - | -1.92 | -2.60 | -2.36 | -3.24 | -0.62 | - | - | - | - | - | - | - | ||||||||||||
| High Estimate | -5.26 | -3.28 | -2.80 | - | - | - | -0.09 | -0.33 | -0.37 | -0.40 | -0.46 | -0.41 | -0.06 | 0.26 | -0.01 | ||||||||||||
| Low Estimate | -6.28 | -3.86 | -3.00 | - | - | - | -0.11 | -0.41 | -0.43 | -0.46 | -0.56 | -0.45 | -0.06 | 0.22 | -0.01 | ||||||||||||
| Consensus Estimate | -5.77 | -3.57 | -2.90 | - | - | - | -0.10 | -0.37 | -0.40 | -0.43 | -0.51 | -0.43 | -0.06 | 0.24 | -0.01 |